

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Substitute for Form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/564,579
				Filed	January 13, 2006
				First Named Inventor	Daisuke ISHII
				Group Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	06019/HG

## U.S. PATENT DOCUMENTS

Exam. Inits <sup>a</sup>	Cite No <sup>1</sup>	Document Number	Kind Code <sup>2</sup>	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion

## FOREIGN PATENT DOCUMENTS

Exam Inits <sup>a</sup>	Cite No <sup>1</sup>	offc <sup>3</sup>	Document Number <sup>4</sup>	Kind Code <sup>5</sup>	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T <sup>6</sup>
N-G		WO	02/14280	A1	ONO PHARMACEUTICAL CO., LTD.	02-21-2002		*
		JP	2003-089637	A	NIKKEN CHEM CO LTD	03-28-2003		*
		JP	2002-179572	A	NIKKEN CHEM CO LTD	06-26-2002		*
		JP	2001-520196	A	SMITHKLINE BEECHAM CORP.	10-30-2001		
N-E		WO	99/20280	A1	SMITHKLINE BEECHAM CORP.	04-29-1999		**

Examiner Signature		Date Considered	8/15/07
-----------------------	---	--------------------	---------

\* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Place a check here if English translation is attached.

DATE MAILED: April 7, 2006

\*ENGLISH-LANGUAGE ABSTRACT ENCLOSED

\*\*WO 99/20280 IS A RELATED FAMILY MEMBER OF JP 2001-520196

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/564,579
				Filing Date	January 13, 2006
				First Named Inventor	Daisuke ISHII
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	06019/HG

**OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
N		SCHMIDT B.M.W. et al., "The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis," <u>Journal of Allergy and Clinical Immunology</u> , 2001, Vol. 108, No. 4, pp. 530 to 536.	
<div style="display: flex; justify-content: space-between;"> <div>Examiner Signature</div> <div></div> <div>Date Considered</div> <div>8/15/07</div> </div>			

\* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Place a check here if English translation is attached.

DATE MAILED: April 7, 2006

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/564,579
				Filed	January 13, 2006
				First Named Inventor	Daisuke ISHII
				Group Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	06019/HG

**U.S. PATENT DOCUMENTS**

Exam. Inits <sup>*</sup>	Cite No <sup>1</sup>	Document Number	Kind Code <sup>2</sup>	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion

**FOREIGN PATENT DOCUMENTS**

Exam. Inits <sup>*</sup>	Cite No <sup>1</sup>	Offc <sup>3</sup>	Document Number <sup>4</sup>	Kind Code <sup>5</sup>	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T <sup>6</sup>
		WO	02/14280	A1	ONO PHARMACEUTICAL CO., LTD.	02-21-2002		*
		JP	2003-089637	A	NIKKEN CHEM CO LTD	03-28-2003		*
		JP	2002-179572	A	NIKKEN CHEM CO LTD	06-26-2002		*
		JP	2001-520196	A	SMITHKLINE BEECHAM CORP.	10-30-2001		
		WO	99/20280	A1	SMITHKLINE BEECHAM CORP.	04-29-1999		**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Place a check here if English translation is attached.

DATE MAILED: April 7, 2006

\*ENGLISH-LANGUAGE ABSTRACT ENCLOSED

\*\*WO 99/20280 IS A RELATED FAMILY MEMBER OF JP 2001-520196

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/564,579
				Filing Date	January 13, 2006
				First Named Inventor	Daisuke ISHII
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	06019/HG
<b>OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
		SCHMIDT B.M.W. et al., "The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis," <u>Journal of Allergy and Clinical Immunology</u> , 2001, Vol. 108, No. 4, pp. 530 to 536.			
Examiner Signature				Date Considered	

\* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Place a check here if English translation is attached.

DATE MAILED: April 7, 2006